PT  - JOURNAL ARTICLE
AU  - YURI TOLKACH
AU  - AXEL MERSEBURGER
AU  - THOMAS HERRMANN
AU  - MARKUS KUCZYK
AU  - JÜRGEN SERTH
AU  - FLORIAN IMKAMP
TI  - Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer
DP  - 2015 Oct 01
TA  - Anticancer Research
PG  - 5443--5451
VI  - 35
IP  - 10
4099  - http://ar.iiarjournals.org/content/35/10/5443.short
4100  - http://ar.iiarjournals.org/content/35/10/5443.full
SO  - Anticancer Res2015 Oct 01; 35
AB  - Background/Aim: The genetic characterization of prostate tumors is important for personalized therapy. The aim of the present study was to investigate the role of previously described prostate cancer-related genes in the genetic characterization of prostate tumors. Materials and Methods: Forty-two genes were selected for expression analysis (real time-quantitative polymerase chain reaction). One normal prostatic epithelial cell line and three standardized prostate cancer cell lines were used. Twenty-eight patients treated with radical prostatectomy were included in the study. Results: The following genes appeared to be possibly related to the metastatic potential of the tumor: ELOVL fatty acid elongase 7 (ELOVL7), enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), gastrulation brain homeobox 2 (GBX2), golgi membrane protein 1 (GOLM1), homeobox C6 (HOXC6), minichromosome maintenance complex component 6 (MCM6), marker of proliferation Ki-67 (MKI67), mucin 1, cell surface associated (MUC1), MYC binding protein 2, E3 ubiquitin protein ligase (MYCBP2), somatostatin receptor 1 (SSTR1), topoisomerase (DNA) II alpha 170 kDa (TOP2A) and exportin 6 (XPO6). Six genes were differentially expressed in patients with localized and locally advanced cancer (GOLM1, GBX2, XPO6, SSTR1, TOP2A and cell division cycle associated 5, CDCA5) and three genes (HOXC6, Cyclin-dependent kinase inhibitor 2A (CDKN2A) and MYC binding protein 2, E3 ubiquitin protein ligase, MYCBP2) in patients with a low vs. high Gleason grade/sum. Conclusion: Some of the investigated genes show promising prognostic and classification features, which might be useful in a clinical setting, warranting for further validation.